Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

AbbVie Inc. Director's Dealing 2018

Dec 13, 2018

29755_dirs_2018-12-12_b0d9780e-bce0-4a59-b52a-7cbfb61047fc.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2018-12-10

Reporting Person: Stewart Jeffrey Ryan (SVP, US Commercial Operations)

Holdings (Non-Derivative)

Security Shares Ownership
Common stock, $0.01 par value 29478 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Option (right to buy) $51.42 2024-02-19 Common stock (25290) Direct
Option (right to buy) $58.88 2025-02-18 Common stock (27690) Direct
Option (right to buy) $54.86 2026-02-17 Common stock (21810) Direct
Option (right to buy) $61.36 2027-02-15 Common stock (26110) Direct
Option (right to buy) $114.36 2028-02-14 Common stock (16070) Direct

Footnotes

F1: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 8,430 shares on 2/20/2015, as to 8,430 shares on 2/20/2016 and as to 8,430 shares on 2/20/2017.

F2: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 9,230 shares on 2/19/2016, as to 9,230 shares on 2/19/2017 and as to 9,230 shares on 2/19/2018.

F3: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 7,270 shares on 2/18/2017 and as to 7,270 shares on 2/18/2018, and becomes exercisable as to 7,270 shares on 2/18/2019.

F4: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable as to 8,704 shares on 2/16/2018, and becomes exercisable as to 8,703 shares on 2/16/2019 and as to 8,703 shares on 2/16/2020.

F5: Employee stock option granted pursuant to the AbbVie 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable as to 5,357 shares on 2/15/2019, as to 5,356 shares on 2/15/2020 and as to 5,357 shares on 2/15/2021.